Avivia is a Dutch independent pharmaceutical R&D company engaged in drug (re)formulation, repurposing and repositioning. Our expertise and capabilities are centered around the development of value-added generic drugs, life cycle management of branded drug products, and complex formulation and CMC development of new drug products (NCE).

They operate a hybrid business model combining specialized CRO service activities with internal product development programs, whereby in both cases, they approach ‘development’ as not just offering a technical solution but always part of a broader product-oriented strategy.

For more information about Avivia, visit their website.